A recent study suggested that IL-6 is one of the cytokines responsible for immune dysregulation or macrophage activation syndrome in severe COVID-19 patients, and the use of Tocilizumab partially rescued SARS-CoV-2 associated immune dysregulation [51]. The gene discussed is IL6; the disease is macrophage activation syndrome.